Your shopping cart is currently empty

I-152 is a coupling of N-acetylcysteine and β-mercaptoethylamine. I-152 has antiproliferative, antiviral, and immunomodulatory activities. I-152 is used in the study of viral infections because it activates NRF2 and ATF4 signaling.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $78 | - | In Stock | |
| 5 mg | $210 | 7-10 days | 7-10 days | |
| 10 mg | $360 | 7-10 days | 7-10 days | |
| 25 mg | $619 | 7-10 days | 7-10 days | |
| 50 mg | $993 | 7-10 days | 7-10 days | |
| 100 mg | $1,590 | 7-10 days | 7-10 days |
| Description | I-152 is a coupling of N-acetylcysteine and β-mercaptoethylamine. I-152 has antiproliferative, antiviral, and immunomodulatory activities. I-152 is used in the study of viral infections because it activates NRF2 and ATF4 signaling. |
| In vitro | When I-152 is treated with RAW 264.7 cells at a concentration of 1 mM, it decreases the level of NRF2 mRNA after 1 h or 2 h; treatment for 0-60 min not only decreases the levels of NRF2 and p53, but also increases the expression of ATF4. In addition, at concentrations of 0.062, 0.125, 0.25, or 1 mM, I-152 was able to increase the levels of Gclc mRNA and Chac1 mRNA after 6 h or 24 h, and increase Chop mRNA expression after 6 h. The expression of Chac1 mRNA was also increased at concentrations of 0.062, 0.125, 0.25, or 1 mM. I-152 also increased GSH levels in RAW 264.7 cells when treated at concentrations of 0.062, 0.125, 0.25, or 1 mM for 2 hours. At a concentration of 1 mM, I-152 treatment for 1 h, 2 h, 6 h and 24 h activated the expression of ATF4 mRNA in RAW 264.7 cells; whereas treatment for 24 h and 48 h produced cytotoxicity and inhibited the growth of RAW 264.7 cells. [1] |
| Synonyms | I152 |
| Molecular Weight | 264.37 |
| Formula | C9H16N2O3S2 |
| Cas No. | 311343-11-0 |
| Smiles | [C@H](C(NCCSC(C)=O)=O)(NC(C)=O)CS |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (302.61 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (12.48 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.